NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by WallStSense.com

CNBC's Fast Money Guy Adami thinks that investors should sell NetApp Inc. (NASDAQ: NTAP) tomorrow and take the profits. NetApp Inc. (NTAP) gained 4.09% and closed at $30.83.

Gary Kaminski would buy Clorox (NYSE: CLX), as he believes that it has a good fundamentals and a potential of a deal is always present with them, in his opinion. Clorox (CLX) fell 1.40% today at $59.85.

Pete Najarian likes King Pharmaceuticals (NYSE: KG). He spotted unusual options activity in trading with Kings Pharma (KG) and thinks it is going up. Investors are a buying December 12.5 calls. King Pharma (KG) jumped 5.09% today.

Joe Terranova would buy natural gas futures as they bottomed in his opinion.

The major indexes fell for the second day in a row, with the Dow closing down 0.9%, the S&P 500 falling 1.3% and the Nasdaq slipping 1.7%.

The major indexes fell for the second day in a row, with the Dow closing down 0.9%, the S&P 500 falling 1.3% and the Nasdaq slipping 1.7%.

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5127022 for the full story.

King Pharmaceuticals (NYSE: KG) hit a new 52-Week high of $11.91 so far today. Currently the stock is up $0.67 (5.98%) to $11.87 on 4,102,031 shares traded. Today's high is up $6.01 ...(Click the story link or go to http://www.marketintelligencecenter.com for the full story)

Today’s tickers: CVS, LIZ, ITMN, MA, V, RF, KG, HW, WSM, AEP & NTAP

CVS - CVS Caremark Corp. – Shares of the pharmacy retail chain are up 1.5% to $31.11 perhaps due, in part, to the ‘buy’ rating it received at UBS today. Optimistic options activity took place in the December contract as one investor initiated a bullish risk reversal. It appears the trader sold 4,400 puts at the December 31 strike for an average premium of 94 cents apiece in order to finance the purchase of the same number of calls at the higher December 32 strike for 63 cents each. The investor pockets a 31 cent credit on the trade, which he retains in full as long as shares remain above $31.00 through expiration. Additional profits accumulate if CVS’s shares rally above $32.00.

LIZ - Liz Claiborne, Inc. – A 15,000-lot covered call in the January 2011 contract on Liz Claiborne today suggests shares are likely to recover, albeit at a glacial pace. Shares of the apparel and accessories retailer suffered a 5% decline to $4.55 during the trading session. One investor effectively purchased shares of the underlying stock for $3.30 apiece by selling 15,000 calls at the January 2011 5.0 strike for a premium of 1.25 each. Thus, the trader stands ready to accrue gains of 51% if shares of LIZ appreciate to $5.00 by expiration. The long-term positioning of the covered call play provides several advantages to the investor. One advantage is that the call options do not expire for another 13 months, which leaves ample time for LIZ’s shares to appreciate up to the strike price of $5.00. The 15,000-lot call transaction represents nearly 50% of the total existing open interest on LIZ of 31,502 contracts. Note that shares last traded above $5.00 yesterday at approximately 10:35 am (EDT).

ITMN - InterMune, Inc. – A bull call spread on the biotechnology company today suggests shares could rally significantly by expiration in April 2010. Bullish options activity on the stock belies the more than 3% decline in ITMN’s shares during the session to $10.94. The call spread involved the purchase of 3,750 calls at the April 15 strike for an average premium of 2.25 each, marked against the sale of the same number of calls at the higher April 25 strike for 75 cents apiece. The net cost of the transaction amounts to 1.50 per contract. The optimistic investor is positioned…

(CVS) - CVS Caremark Corp. - Shares of the pharmacy retail chain are up 1.5% to $31.11 perhaps due, in part, to the ‘buy’ rating it received at UBS today. Optimistic options activity took place in the December contract as one investor initiated a bullish risk reversal. It appears the trader ...

Today's tickers: MA, V, RF, KG, HW, WSM, AEP & NTAP[More...]

 

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.SunLink Health Systems, Inc. (NYSE:SSY) announced earnings from continuing operations for its fiscal quarter ended September 30, 2009 of $549,000, or $0.07 per fully diluted share, compared to a loss from continuing operations of $603,000, or $0.08 per fully diluted share, for the quarter ended September 30, 2008.Enzo Biochem Inc. (NYSE:ENZ) announced today that David Goldberg, Vice President, Corporate Development, will speak on the Company’s extensive oral immune regulation platform at the Windhover TA Partnerships 2009 conference in Boston, MA, on Wednesday, November 18, 2009, where Enzo’s EGS21, an orally administered beta glucosylceramide formulation, now undergoing clinical study, was named one of this year’s “top 10 inflammatory/autoimmune projects to watch.”Pro-Pharmaceuticals, Inc. (OTCBB: PRWP), a developer of galectin-targeted, carbohydrate therapeutic compounds to treat cancer and fibrosis, today reported its financial results for the third quarter and first nine months of fiscal 2009.Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to treat chronic and acute wounds, today announced that its development partners, Bayer Animal Health divisions in China and Taiwan, recently secured regulatory approvals in both those countries to develop and market Microcyn-based Vetericyn™ products for their respective animal healthcare markets.Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, announced today that it will present at the Lazard Capital Markets 6th Annual Healthcare Conference in New York City.Ore Pharmaceutical Holdings Inc. (NASDAQ:ORXE) today reported financial results and provided an operational update for the third quarter ended September 30, 2009.China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics," "the Company"), a leading Chinese firm specializing in the research, development, manufacture, marketing and distribution of probiotics dietary supplements, today announced it will host a conference call at 11:00 a.m. EST on Tuesday, November 17, 2009, to discuss the Company's financial results for the second quarter of its 2010 fiscal year.NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a clinical-stage biopharmaceutical company developing first-in-class anti-infective products for the treatment and prevention of a wide range of infections, today reported financial results for the third quarter ended September 30, 2009.Exelixis, Inc. (Nasdaq:EXEL) announced today that Frank Karbe, the company’s executive vice president and chief financial officer, will present at Lazard’s 6th Annual Healthcare Conference at 11:00 a.m. EST / 8:00 a.m. PST on Wednesday, November 18, 2009 in New York.Columbia Laboratories, Inc. (Nasdaq: CBRX) today commented that nothing fundamental in the Company’s operations has changed to cause the current market activity in its Common Stock.Talecris Biotherapeutics (Nasdaq: TLCR) and N.C. Gov. Bev Perdue jointly announced today that the company will expand its manufacturing facilities in Clayton, creating 259 new jobs over the next seven years.PanGenex Corporation (Pink Sheets:PGCX), a global nutraceutical and dietary supplement manufacturer and marketer, is pleased to announce today that two of the nation's leading interventional cardiologists, Dr. Steven Yakubov and Dr. Mark Turco, have joined the Company's Scientific Advisory Board.Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 1:40 p.m. ET will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com.Genzyme Corp. (Nasdaq:GENZ) announced today that it has issued letters to U.S. healthcare providers regarding its enzyme replacement products Cerezyme® (miglucerase for injection), Fabrazyme® (agalsidase beta), Myozyme® (alglucosidase alfa), Aldurazyme® (laronidase), as well as Thyrogen® (thyrotropin alfa for injection), filled at its Allston Landing manufacturing facility.King Pharmaceuticals, Inc. (NYSE:KG) today announced plans to present at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18, 2009, at 2:15 pm EST, at the St. Regis Hotel in New York, New York.MedaSorb Technologies Corporation (OTCBB:MSBT) and its wholly-owned subsidiary, CytoSorbents, Inc., today announced the filing of Q3 2009 financial results as reported in its Form 10-Q with the SEC.

King Pharmaceuticals, Inc. (KG) reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents. Despite revenues increasing 19.3% from the year-ago period, earnings declined 25.6% from the year-ago quarter mainly due to higher operating expenses. Total revenues came in at $463.3 million. The primary growth drivers were the Animal [...]

($KG) King Pharmaceuticals Beats Consensus, but Earnings Down

Two Veteran Wall Street Analysts discuss: (Val:) ABT, ENDP, MRX; (Vern:) PL, KG, AMN

King Pharmaceuticals, Inc.  (Public, NYSE:KG) stock has finally inched up 4% since Tuesday (10/16) after falling 49% since this summer.  Shares of the King are in the $10 range which has made its P/E more reasonable with a value of 8.5.  Friday KG announced they are eliminating 20% of their workforce and we think its the right move for shareholders.

Yesterday (10/19) Citi Investment Research analyst Andrew Swanson upgraded King to "Hold" from "Sell", saying the job cuts were the right move.  Swanson expects King's earnings to keep falling for the next few quarters, but said the stock price, which is trading around two-year lows, now reflects that risk.

King Pharma's game plan is to devote more attention to its painkilling drugs, and because it will need fewer sales representatives to sell those drugs, it could cut its 1,200-person sales force in half.  "The company can now focus on its pain portfolio, where it is looking to reinvigorate soft prescription trends for Avinza and is awaiting Phase III data for Remoxy," said Swanson.

Positive trial data could lift the stock, he said, but painkiller Remoxy is the only promising drug in King's pipeline and it will not reach the market for at least a year. Swanson kept a price target of $12 per share.

Last month, a federal appeals court ruled to overturn the patent supporting Altace, in a case brought against King and distribution partner Sanofi-Aventis by Indian generic drug maker Lupin Ltd. King appealed the ruling, but said it will focus on other drugs.

King stock has lost nearly half its value over the last three months as investors worried about the Altace ruling, along with challenges to the patent on King's muscle relaxant Skelaxin and greater generic competition for its hemostatic product, Thrombin-JMI. The three drugs are King's top sellers.  The Masters like the money KG has been pulling in the past two years and we're starting to like the odds on King:

King Pharma's Financials (In millions of USD)

If King Pharma can continue to get its act together, there's no reason this stock can't return to the $20 range.

---

Article by Ted Gottsegen

Contributor at TheStockMasters.com

Disclaimer: The Author does not hold any positions or shares in the securities mentioned in this publication nor does he stuff his shorts.

---

Our Original newsletter that has enlightened our subscribers for over a year. It contains What to Buy, What to Sell, and Market Commentary. We have a 17.5% return since October 2006 and the average wait for a return is only 3.61 months and we have the track record to prove it (click here to view Master Picks track record). We've had great feedback, and in turn have already created a unique following of thousands of Stockmasters. Our asking price is only $45 for a 12 month subscription.  

Two Wall Street Analysts Review Value Line's April 20, 2007 Edition

Intro: Elvis birthday singing the Hawaiian Wedding Song. Lots of buzz at the CSE on Microsoft’s plans to integrate the experiences of WEB 2.0 and IPTV with XBOX 360. The largest “living room” social network has 5 million members. Just in time for the 2007 holiday season. New site: Stockpickr.com in conjunction with James Altucher who writes for the Financial and is a hedge fund manager. Investors Business Daily ran an ad for[CVDT] a month ago. How is it doing? American Idol is streaming this season. FremantleMediaRTLGroupBertlemannAG will handle this McDonald{MCD] and MasterCard[MA] doing ads. Pete from Optionsmonster: AtheroGenics[AGIX] call spread calls up to 70? Stock is trading in the 12 range. CEO will be speaking on Jan 10th. King Pharmaceuticals [KG] 17 ½ calls. This hit late Friday. Listen live 9am CST on mn1.com Updates at 12Noon Live.